{"name":"Yeon Hee Park","slug":"yeon-hee-park","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Ribociclib with fulvestrant","genericName":"Ribociclib with fulvestrant","slug":"ribociclib-with-fulvestrant","indication":"Other","status":"phase_2"},{"name":"Sacituzumab Govitecan with pegfilgrastim","genericName":"Sacituzumab Govitecan with pegfilgrastim","slug":"sacituzumab-govitecan-with-pegfilgrastim","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"Ribociclib with fulvestrant","genericName":"Ribociclib with fulvestrant","slug":"ribociclib-with-fulvestrant","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Sacituzumab Govitecan with pegfilgrastim","genericName":"Sacituzumab Govitecan with pegfilgrastim","slug":"sacituzumab-govitecan-with-pegfilgrastim","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxPakNDYllwLVFNdi1BTl9PS0xoT2gyT0pTRXRwbGtlZVlUb184ZFRESUpDVEsyMDNqWFdaYlg4YWJnZHpjM0dhQVBTSkp5S0tqRnhwS2JzSThyMUtSX215Z2xPVHZON0tCMlMyWUtFLUZCU0FDWFVFbjhHNjJGQUd4bdIBlAFBVV95cUxPNnR6RXZsLTItMTl0ZWlwREd0emVVLW5KRjg1VzVaRmxsdUQwTklIQUl6SFRnYW52R2pXd1RsQmVuRUZ0Slh2QTg4ZkNWUC1QVFJFNW5lMU1HWUtnVF9tWV9DY0xfRTdVTWdzZEhyT1NBWDJOcnhSamQ5Z2twU3U5V0c4cnNyUGQ0X2RleEsxMDdJYkZW?oc=5","date":"2026-03-12","type":"pipeline","source":"Chosunbiz","summary":"Hanmi Science moves to replace CEO as outsider Hwang Sang-yeon poised to lead - CHOSUNBIZ - Chosunbiz","headline":"Hanmi Science moves to replace CEO as outsider Hwang Sang-yeon poised to lead - CHOSUNBIZ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxPSk1zOTZHU0dXWlpJT0tXZ05OcTNLd25TUmM1WFNfNEhPYk1kRElRNFRSbDVzNXR0d1FlcHZ2VWhlZkFnWVQxRnRFSDIzb3NOUi1aOUwyMVJKck5tVV9vLXZjWW1nd01BaUtwdGxQSS10ZFptU1oxem5zeEY3V1JWNjh4Rm44ZVpyb3lZNUVzellnTGl1YU1LSnpQaW1KYVkxVWc?oc=5","date":"2026-03-12","type":"pipeline","source":"Seoul Economic Daily","summary":"Hanmi Pharmaceutical Replaces CEO to End Major Shareholder Dispute - Seoul Economic Daily","headline":"Hanmi Pharmaceutical Replaces CEO to End Major Shareholder Dispute","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxNRlBEREpNOHNGaWQ3NEdJOUxUUFNrTi1fYnNReFU3cEZIMFczODFMX0tCZklmVDlzTUhCSFRGQnBOS2FfaGJYWjBTVG9HY3dZREZ1R3BfNzl4cUkxTnM1X1UxRWlzejRrRGZtb2RQbk5GN2x5VldCSDVSUTVnUndvVXF3SGY?oc=5","date":"2026-01-27","type":"pipeline","source":"조선일보","summary":"Trump Raises Tariffs on Korean Automobiles, Pharmaceuticals to 25% - 조선일보","headline":"Trump Raises Tariffs on Korean Automobiles, Pharmaceuticals to 25% - 조선일보","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE5GZ0FDdS1RQnRpRC1uX184LURLWEJzbWJXZVpqd0tvU0JpNlhVelpldWVtVTg2OTNYdmZ0MkdXaTFiN2JlUFJKYjhfZ3MySVU1ZHJHS1hoa1N1QzNRYkdWay04TlRsVlVEZGFWSVpR0gFyQVVfeXFMTnBMU1IxRHIzYnJaZ1dLbnJRTTd0N2VuWk9oVk9xbkxwS05DcktEeHVRcmVsZzdWOHdSZEJHZ09wSC1aRkpxVElsampMZVdSNUI2dWg4N2x1czY0aFgydzZkcWk0TFBqR2N0Y05FYlJRb1BR?oc=5","date":"2025-10-20","type":"pipeline","source":"koreabiomed.com","summary":"[ESMO 2025] Enhertu outperforms Kadcyla in HER2-positive early breast cancer - koreabiomed.com","headline":"[ESMO 2025] Enhertu outperforms Kadcyla in HER2-positive early breast cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFBCY0k5Y29hWW1GV2VqNHkxT203MzAtdHA4X3pONWNaVTVqLVYzNnZVb1B0dWpRdWNsbldFeWFWdnBicHNCV0JrUUtxWFhmakZ4RzJ6XzY0c3RvUVZJcGhOY3l1YVNKdHB5RGVKOXhR0gFyQVVfeXFMTkhTbURmNUxaNjA0bk5ibEdDc01FTjRBaURyV0ZhREcwZ2xrekRzRDhONndBMGlBQWQ1dkZGcEE5MURZeVVYZ2tLTWZZRHE1X19ZZ0htVGZiZDctbkF0dEhJck1oWm82U3Iycm1udXkxRHdR?oc=5","date":"2025-10-20","type":"pipeline","source":"koreabiomed.com","summary":"[ESMO 2025] Kisqali adjuvant therapy maintains efficacy at 5th year - koreabiomed.com","headline":"[ESMO 2025] Kisqali adjuvant therapy maintains efficacy at 5th year","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE1jM25La1l1NGxRTVRjYmZHM19rWWVSS3dSVUNJMXhvb25pc2xHanpXMjRuWEJrVEtoUUtpbFRiZHVkZW9lLXlUak1pRkZOc3Q1WkdVOU9ERFRFYjc4SXRF?oc=5","date":"2025-10-08","type":"trial","source":"Nature","summary":"Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial - Nature","headline":"Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DEST","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTE44N0VTb3lrNFFNbFB6d1B0OWhPTTFfVmdlczc3QVR3Y3Y2NGVoVUxTUjAzeGdDZjRPM2gxcGpVRS1wMnQ0Wk9UUG5tREMxMGZkNmxGb3N3bVEzaVpxQ250UnNZMFE5Nk1vb3lUdmNYV3hMTkk?oc=5","date":"2025-02-27","type":"trial","source":"tandfonline.com","summary":"CAMBRIA-1 & CAMBRIA-2 phase III trials: camizestrant versus standard endocrine therapy in ER+/HER2– early breast cancer - tandfonline.com","headline":"CAMBRIA-1 & CAMBRIA-2 phase III trials: camizestrant versus standard endocrine therapy in ER+/HER2– early breast cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidkFVX3lxTE5MbG9pdW5ucmFzRy1lZW0zdm1zRUN1WjdITldmWEFEdFF1M0NJT0lUSG9aRWx2YmppSEhaLXJUYXdpNHAxclZIZG9yUUMzd1VMX0QweVlKSTJyV2o1SDIxeHA2alJaZWoxdGdkVU81ekZWMGlReVE?oc=5","date":"2025-02-20","type":"pipeline","source":"MedPage Today","summary":"No OS Boost With Palbociclib and Endocrine Therapy in Premenopausal Breast Cancer - MedPage Today","headline":"No OS Boost With Palbociclib and Endocrine Therapy in Premenopausal Breast Cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE5WY2tJYTBlVGRlZWQyZll4dUpoZEw4QjdTVGNoRkwxY1pVTHFuSGNHR29NOWVzaUxBOF9BakJKbUlodlI3U1JRNHpMczE1bUZkYlY3bi1IUndsblRmTlV3?oc=5","date":"2025-01-21","type":"pipeline","source":"Nature","summary":"Pembrolizumab and chemotherapy in high-risk, early-stage, ER - Nature","headline":"Pembrolizumab and chemotherapy in high-risk, early-stage, ER","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMib0FVX3lxTE9CX0s0NUp5Vzlsb0Iwbm1XQ0RzeGIzVVhSRE8xVGlwMmNHNmJhWENQQk15WkttZ0ZwUnhCbjRiODlVQU5ZRjJ1dGdOTklTWXpTLWxoQmowRFhIVVh2b1FmcGdyZF9mNjRfbzFTN3pudw?oc=5","date":"2024-11-21","type":"pipeline","source":"Wiley Online Library","summary":"Self-Assembled Peptide-Derived Proteolysis-Targeting Chimera (PROTAC) Nanoparticles for Tumor-Targeted and Durable PD-L1 Degradation in Cancer Immunotherapy - Wiley Online Library","headline":"Self-Assembled Peptide-Derived Proteolysis-Targeting Chimera (PROTAC) Nanoparticles for Tumor-Targeted and Durable PD-L1","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTFBqaVZ1ZXBrbUwtUjZaUDk1aENIS0MzZzRRSC1JeXd6QWN1dnhRVUU4WUlRMS1nQmZRT2luUFMwYUtkNEI4bk5HNHdnS1FNSDlmcWQxWVpCQklDX29DX2w5cA?oc=5","date":"2022-03-23","type":"pipeline","source":"NEJM","summary":"Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer - NEJM","headline":"Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTFBjNU12bVpFTFZaVnFhVFhjNlh4bFhKSDJNOTdtRDd6YWVTSFFMbkNCcHF3eXctOUVHSmYybWZ1bTFZaGpJWS1ORllBUlBia3p4TmFHbkhBX0RiTXVuRFg3Tg?oc=5","date":"2019-12-11","type":"pipeline","source":"NEJM","summary":"Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer - NEJM","headline":"Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":2},"enrichmentLevel":2,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}